Shareholder letter - Monday May 13, 2013
Link to document.
RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.
* In March 2011 the FDA placed a “clinical hold” on our Phase 2 AMI trial due to cGMP issues at a contract manufacturer’s site formulating RGN-352. The timing for the resumption of this trial is unclear. The reader is referred to our press releases dated March 16 and April 14, 2011.
May 13, 2013
RegeneRx Issues Letter to Shareholders
April 1, 2013
RegeneRx Issues $225,000 Convertible Note